cas 77215-54-4|| where to buy Boc-Dap-OtBu

Product Name:Boc-Dap-OtBu

IUPAC Name:tert-butyl (2S)-3-amino-2-{[(tert-butoxy)carbonyl]amino}propanoate

Packing Unit	Available Stock	Price($)
CM255003-1g	1-2 Weeks	ǫȖƃ
CM255003-5g	3-4 Weeks	ƃŪƥ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 77215-54-4 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:77215-54-4; Molecular Formula:C12H24N2O4; Melting Point:-; Smiles Code:O=C(OC(C)(C)C)[C@@H](NC(OC(C)(C)C)=O)CN; Density:

: Catalog Number:CM255003; Molecular Weight:260.33; Boiling Point:369.0±37.0°C at 760 mmHg; MDL No:; Storage:Store at 2-8°C.

: Amino Acids and Peptides; Amino acids are organic compounds containing a basic amino group and an acidic carboxyl group. Because amino acids contain both amino and carboxyl groups, they can be polymerized in an end-to-end manner, removing a molecule of water to form a covalent amide bond or peptide bond. Many amino acids are linked together end to end to form a polypeptide. Amino acids and peptides are important components in the fields of medicine and life sciences.; amino acids wholesale; if you are finding amino acids wholesaler in china, we will be your best choose! We have our own factory, so we can give you a cheap price!

: Upacicalcet; Pathalys pharma secures $105 million series B financing. Oversubscribed financing paves path to NDA submission and pre-commercialization efforts for upacicalcet.
Upacicalcet is a novel calcimimetic that can be delivered intravenously at the end of the hemodialysis session via pre-filled syringe and has been demonstrated to effectively reduce levels of parathyroid hormone(PTH) and may have a better tolerability profile for patients. Upacicalcet can be used in secondary hyperparathyroidism (SHPT) to address an unmet need in the management of advanced chronic kidney disease (CKD).